In another small claims-based study (2016–2021) of the 1L treatment of patients with advanced NSCLC and programmed death ligand 1 (PDL1) expression below 50% who made at least one claim for ICI-based chemotherapy, total adjusted all-cause medical costs were higher with ICI in combination than with chemotherapy alone (based on 88 patients in each group) [28]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.